Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$821K Sell
2,334
-326
-12% -$116K 0.43% 55
2025
Q4
$871K Sell
2,660
-193
-7% -$61.2K 0.24% 94
2025
Q3
$838K Sell
2,853
-529
-16% -$153K 0.24% 97
2025
Q2
$944K Sell
3,382
-378
-10% -$107K 0.25% 94
2025
Q1
$1.17M Sell
3,760
-305
-8% -$90.1K 0.34% 69
2024
Q4
$1.06M Sell
4,065
-3
-0.1% -$890 0.3% 76
2024
Q3
$1.31M Sell
4,068
-30
-0.7% -$9.81K 0.39% 56
2024
Q2
$1.28M Buy
4,098
+455
+12% +$134K 0.42% 53
2024
Q1
$1.01M Buy
3,643
+1,321
+57% +$387K 0.37% 62
2023
Q4
$669K Buy
+2,322
New +$633K 0.34% 67
2023
Q3
Sell
-3,035
Closed -$674K 113
2023
Q2
$674K Buy
3,035
+1,618
+114% +$375K 0.29% 82
2023
Q1
$343K Buy
1,417
+15
+1% +$3.68K 0.26% 75
2022
Q4
$368K Buy
+1,402
New +$376K 0.31% 66

Other funds holding AMGN

TFB Advisors's AMGN Position: Q1 2026 in Review

TFB Advisors reduced its Amgen (AMGN) stake by 12% in Q1 2026, selling an estimated $116K and leaving 2,334 shares worth $821K. The position accounts for 0.43% of the portfolio, ranked #55.

TFB Advisors first reported a position in AMGN in Q4 2022 and has held it in 13 quarters since. The position peaked at $1.31M in Q3 2024. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • TFB Advisors held 2,334 shares of Amgen worth $821K as of Q1 2026.
  • TFB Advisors sold 326 Amgen shares in Q1 2026, an estimated $116K.
  • Amgen made up 0.43% of TFB Advisors's portfolio in Q1 2026, its #55 holding.
  • TFB Advisors first reported a position in Amgen in Q4 2022 and has held it in 13 quarters since.
  • TFB Advisors's Amgen position peaked at $1.31M in Q3 2024.
  • 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on TFB Advisors's 13F filing for Q1 2026, filed 20 Apr 2026.